We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ovatio DR and VR Implantable Cardioverter Defibrillators Post-approval Study (Post-Ovatio)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00586378
First Posted: January 4, 2008
Last Update Posted: March 2, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
ELA Medical, Inc.
  Purpose
The purpose of this post-approval study is to confirm the safety and effectiveness of Ovatio DR and VR ICDs

Condition Intervention Phase
Sudden Cardiac Death Device: Ovatio DR and Ovatio VR Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Ovatio DR and VR Implantable Cardioverter Defibrillators Post-approval Study

Resource links provided by NLM:


Further study details as provided by ELA Medical, Inc.:

Primary Outcome Measures:
  • The percentage of patients free from complications [ Time Frame: 6 months ]
  • Shock effectiveness for VT/VF [ Time Frame: 6 months ]

Enrollment: 85
Study Start Date: April 2006
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: Ovatio DR and Ovatio VR
    implantable cardioverter defibrillator
    Other Names:
    • Ovatio DR 6550 Dual-Chamber ICD
    • Ovatio VR 6250 Single-Chamber ICD
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Candidates will come from the investigator's general ICD population who meet any of the accepted indications for an ICD implant according to the "ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death" (Zipes et al., JACC Vol. 48, No. 5, Sept. 2006:1064-1108).

Exclusion Criteria:

  • Ventricular tachyarrhythmia that may have transient or reversible causes such as: acute myocardial infarction, digitalis intoxication, drowning, electrocution, electrolyte imbalance, hypoxia, sepsis, or unstable ischemic episodes
  • Incessant tachyarrhythmia
  • Implanted pacemaker
  • Primary disorder of bradyarrhythmia or atrial tachyarrhythmia
  • Of minor age
  • Pregnant
  • Participating in another clinical study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00586378


Locations
United States, Arizona
Banner Baywood
Mesa, Arizona, United States, 85206
Sponsors and Collaborators
ELA Medical, Inc.
Investigators
Study Director: Mark J Schwartz, MS ELA Medical, Inc.
  More Information

Responsible Party: ELA Medical, Inc.
ClinicalTrials.gov Identifier: NCT00586378     History of Changes
Other Study ID Numbers: ITAC05
First Submitted: December 21, 2007
First Posted: January 4, 2008
Last Update Posted: March 2, 2012
Last Verified: March 2012

Additional relevant MeSH terms:
Death
Death, Sudden, Cardiac
Pathologic Processes
Heart Arrest
Heart Diseases
Cardiovascular Diseases
Death, Sudden